FLT1 is an inclusion criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain FLT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open) [4].

FLT1 is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FLT1 status and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (3 open) [4].

FLT1 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain FLT1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [4].

FLT1 is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FLT1 status and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FLT1 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT1 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].